Progress of bispecific antibodies targeting immune checkpoints in treatment of tumors

VernacularTitle:靶向免疫检查点的双特异性抗体在肿瘤治疗中的研究进展
Author: Xiaoqing CHEN ; Fentian CHEN ; Wenxin LUO
From: Cancer Research and Clinic 2021;33(3):221-225
CountryChina
Language:Chinese
Abstract: Immune checkpoint is one of the most effective research targets for tumor immunotherapy. Immune checkpoint inhibitors, mainly programmed death receptor 1 and its ligand 1, have achieved good response rates in various tumor treatments, but some tumors still have low response rates. In recent years, bispecific antibodies have developed rapidly in the field of tumor research, because they can target multiple targets and play a combined role in tumor therapy, and can effectively inhibit tumor immune escape. This article reviews the research progress and clinical status of bispecific antibodies targeting immune checkpoints.